BioMarin (BMRN +2%) gains on an upgrade to Buy at Brean Murray based on increased confidence in...

|About: BioMarin Pharmaceutical Inc. (BMRN)|By:, SA News Editor

BioMarin (BMRN +2%) gains on an upgrade to Buy at Brean Murray based on increased confidence in the timing and outcome of its GALNS program to treat MPS IV. The firm believes the treatment could eventually exceed $500M in sales.